Literature DB >> 6862589

Nifedipine or verapamil as sole treatment of hypertension. An intraarterial study.

B A Gould, R S Hornung, S Mann, V B Subramanian, E B Raftery.   

Abstract

Intraarterial ambulatory blood pressures were recorded prior to and during therapy with two different calcium ion antagonists, nifedipine and verapamil, in two separate groups of patients. In the first group, nine patients were studied off therapy and following a minimum of 6 weeks of nifedipine treatment (dose range, 20 to 60 mg twice daily). A second group of 16 patients followed the identical protocol but were prescribed verapamil (120 to 160 mg, three times daily). During both studies, patients underwent standardized physiological tests including tilt, isometric handgrip, and dynamic bicycle exercise. Both verapamil and nifedipine caused a reduction in blood pressure over most of the 24 hours studied. Nifedipine did not affect heart rate whereas verapamil caused a reduction of approximately 10 bpm. Nifedipine and verapamil did not induce postural hypotension, and the absolute responses to dynamic and isometric exercise were reduced. These results show the efficacy of slow channel inhibitors in the management of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6862589     DOI: 10.1161/01.hyp.5.4_pt_2.ii91

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Verapamil enhanced in vitro chemosensitivity of a murine bladder carcinoma, FCB.

Authors:  R J Ballou; W G Simpson; J I Harty; M T Tseng
Journal:  Urol Res       Date:  1986

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Behavioral performance effects of verapamil in normotensive and renovascular hypertensive baboons.

Authors:  J S Turkkan; R D Hienz
Journal:  Integr Physiol Behav Sci       Date:  1992 Apr-Jun

4.  A multicenter comparison of isradipine and prazosin for treatment of essential hypertension.

Authors:  S L Swartz; L M Gonasun; R G McAllister; U Thadani
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

5.  Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.

Authors:  K Lange Andersen; W Piatkowski; K A Green; W Ottmann
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

6.  Behavioral performance effects of nifedipine in normotensive and renovascular hypertensive baboons.

Authors:  J S Turkkan; R D Hienz
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.

Authors:  M Caruana; M Heber; G Brigden; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 9.  Management of hypertension in actively exercising patients. Implications for drug selection.

Authors:  D Klaus
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.